526953

- Board meeting scheduled for July 20, 2026. - To consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. - Trading window closed from July 01, 2026 until 48 hours post results.

- The trading window for dealing in the Company's securities will remain closed for all Designated Persons from July 1, 2026. - It will reopen 48 hours after the declaration of unaudited financial results for the period ending on June 30, 2026. - This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

- Venus Remedies Limited has disseminated social media communications to shareholders regarding the updation of KYC details. - The company shared links to its posts on Instagram, Facebook, LinkedIn, and X for awareness.

- Venus Remedies Limited secured renewal of its in-house R&D recognition from the Department of Scientific and Industrial Research (DSIR). - This renewal confirms VMRC meets R&D conditions and supports work on antimicrobial resistance, including USFDA QIDP designated VRP-034.

Standalone Revenue for Q4 FY26 was ₹259.01 Cr vs ₹196.74 Cr (▲31.65% YoY), EBITDA was ₹64.07 Cr vs ₹29.32 Cr (▲118.52% YoY), and PAT was ₹43.45 Cr vs ₹14.79 Cr (▲193.78% YoY). EBITDA Margin expanded to 24.73% from 14.90% (▲983bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for FY26.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.59% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY) for the quarter ended March 31, 2026. EBITDA Margin expanded to 24.73% vs 14.90% (▲983bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for the financial year 2025-26.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.74% vs 14.90% (▲984bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for FY2025-26.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.73% vs 14.90% (▲983bps). The Board also recommended a final dividend of ₹10/- per equity share (100%) for FY 2025-26, scheduled to be paid within 30 days of the 37th Annual General Meeting (August 20, 2026).

Consolidated Revenue ₹259.40Cr vs ₹197.66Cr (▲31.24% YoY), EBITDA ₹68.37Cr vs ₹35.77Cr (▲91.15% YoY), PAT ₹47.49Cr vs ₹21.00Cr (▲126.14% YoY). EBITDA Margin 26.36% vs 18.10% (▲826bps). The Board also recommended a final dividend of ₹10/- (100%) per equity share for FY 2025-26, subject to shareholder approval.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.73% vs 14.90% (▲983bps). The board also recommended a final dividend of ₹10/- (100%) per equity share for FY 2025-26.

Venus Remedies Limited received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor, a specialty oncology therapy for autologous transplantation. This is the company's first global approval for Plerixafor and its first Marketing Authorization for a specialty oncology therapy, enabling commercialization in Saudi Arabia. This move advances the company's shift into higher-value specialty injectables in regulated markets, with the Saudi Arabian pharmaceutical market projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033.

Venus Remedies Limited informed the stock exchanges about social media communications made on its official handles (Instagram, Facebook, LinkedIn, and X) regarding awareness to shareholders for updation of KYC details with the company, as per Regulation 30 of SEBI (LODR) Regulations, 2015.